Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safe Stop IPI-NIVO Trial
2024-516938-34-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nivolumab, ipilimumab and pembrolizumab in melanoma, sponsored by Erasmus MC. Primary endpoint: Ongoing response at 12 months. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-516938-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516938-34-00.